| Autor: |
Daniel Martin, Panagiotis Balermpas, Johannes Gollrad, Christian Weiß, Chiara Valentini, Martin Stuschke, Henning Schäfer, Christoph Henkenberens, Jürgen Debus, David Krug, Thomas Kuhnt, Thomas Brunner, Tilman Bostel, Rita Engenhart-Cabillic, Ursula Nestle, Stephanie E. Combs, Claus Belka, Matthias Hautmann, Guido Hildebrandt, Cihan Gani, Bülent Polat, Claus Rödel, Emmanouil Fokas |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Clinical and Translational Radiation Oncology, Vol 23, Iss , Pp 43-49 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2405-6308 |
| DOI: |
10.1016/j.ctro.2020.04.010 |
| Popis: |
Purpose: Anal squamous cell carcinomas (ASCC) are increasing in frequency across the developed world. The 3-year disease-free survival (DFS) in patients with locally-advanced disease is approximately 60% after primary radiochemotherapy (RCT). There is a strong rationale for combining immunotherapy with RCT in patients with ASCC due to its association with human papilloma virus (HPV) infection. Methods/design: RADIANCE is an investigator initiated, prospective, multicenter, randomized phase II trial testing the addition of Durvalumab, a PD-L1 immune checkpoint inhibitor, to standard RCT in 178 patients with locally advanced ASCC (T2 ≥ 4 cm Nany, cT3-4 and/or cN+). In the control arm, patients will be treated with standard mitomycin C (MMC)/5-fluorouracil (5-FU)-based RCT. Intensity-modulated radiotherapy (IMRT) will be applied as follows: PTV_A (primary tumor) T1-T2 |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
